期刊
MOLECULAR PHARMACEUTICS
卷 15, 期 4, 页码 1618-1626出版社
AMER CHEMICAL SOC
DOI: 10.1021/acs.molpharmaceut.7b01164
关键词
cell-penetrating peptide; doxorubicin; andrographolide; liposome; angiogenesis; breast cancer
资金
- 973 Program, China [2014CB931900]
- NFSC [81402883, 81422048, 81673382, 81521005]
- Strategic Priority Research Program of CAS [XDA12050307]
- Scientific Research and Equipment Development Project [YZ201437]
- SANOFI-SIBS Scholarship Program
- Youth Innovation Promotion Association of CAS
- Fudan-SIMM Joint Research Fund [FU-SIMM20174009]
Effective treatment of metastatic (stage N) breast cancers remains a formidable challenge. To address this issue, a cell-penetrating peptide assisted liposomal system was developed for codelivery of doxorubicin and andrographolide. This nanomedicine-based combination therapy showed the ability to inhibit the in vitro migration and invasion of 4T1 cells through the wound healing and transwell invasion assays. Furthermore, this delivery system exhibited the enhanced accumulation in the tumor tissues and deep intratumoral penetration. The synergistic effect of doxorubicin and andrographolide led to an evident inhibition of tumor growth in an orthotopic breast tumor mouse model and efficient prevention of lung metastasis. The therapeutic mechanism was associated with the anti-angiogenesis effect. In conclusion, this nanomedicine-based combination therapy provides a potential method for overcoming metastatic breast cancers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据